HR 1730 117th Congress House Health Advisory bodies Department of Health and Human Services Drug safety, medical device, and laboratory regulation Drug therapy Executive agency funding and structure Food and Drug Administration (FDA) Health technology, devices, supplies Manufacturing Medical research Research administration and funding

Speeding Therapy Access Today Act of 2021

Introduced: March 10, 2021 Introduced by: Bilirakis, Gus M. Republican · Florida See on congress.gov

Everywhere this bill has been 3 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Mar 10, 2021

Referred to the Subcommittee on Health.

Mar 10, 2021

Referred to the House Committee on Energy and Commerce.

Mar 10, 2021

Introduced in House

Plain-English summary Congressional Research Service

Speeding Therapy Access Today Act of 2021

This bill requires and authorizes various actions to accelerate the development of therapies for rare diseases.

The Food and Drug Administration (FDA) shall establish the Intercenter Institute on Rare Diseases and Conditions. The institute shall (1) coordinate engagement with relevant stakeholders, (2) build the FDA's expertise in the review of medical products to treat rare diseases, (3) coordinate regulatory science initiatives related to rare diseases, (4) establish and implement a program to make recommendations to address challenges associated with developing medical products to treat rare diseases in an individual or in very small populations, (5) convene a stakeholder meeting to consider potential amendments to labels for medical products to treat rare diseases, and (6) establish and carry out a program to facilitate voluntary communication between the sponsors of such medical products and third-party payers (e.g., insurance companies).

The bill also authorizes the FDA to make grants to assist in developing practices related to the development and production of individualized therapies or therapies to treat very small populations.

The bill also establishes an advisory committee to advise the FDA on issues related to the development of therapies to treat rare diseases.

What's happening now March 10, 2021

Referred to the Subcommittee on Health.

Committees of jurisdiction 2